Business Wire

CA-ALTIUM

Share
Altium Empowers High School STEM Teachers with a Virtual Electronic Design Curriculum and Tools

In September 2020, Altium LLC, the leading printed circuit board (PCB) software company, launched Upverter Education , a free distance learning initiative to support STEM educators.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005934/en/

“Upverter Education has the opportunity to help high school STEM teachers transition into the virtual classroom. Our goal is to support the next generation of electronics designers of all economic levels by giving them access to free curriculum and professional tools today to prepare them for their innovative careers in the future,” explains Rea Callender, Executive Director of Upverter Education.

The Upverter Education initiative provides the curriculum and resources to guide users through the design, prototyping and manufacturing of electronics engineering concluding with the delivery of students hardware designs. Teachers can utilize the materials to supplement their existing lesson plans, either as standalone units or as a full, 4-6 week educational program.

The program centers around Altium’s Upverter , a free, web-based PCB design tool that’s easy to use in the distance-learning classroom. Upverter’s collaborative and remote capabilities align perfectly with the needs of STEM educators for guiding students through the electronics design process and their exploration of technology and engineering.

Since the launch, the Upverter Education team has formed strategic partnerships with schools around the country and collaborations with leaders in engineering education, including the American Society for Engineering Education, TRYEngineering, First Robotics, and NASA’s Robotics Alliance Project.

Schools within Elk Grove Unified, one of California’s largest school districts, have adopted the Upverter Education program, as well as the North Carolina School of Science and Mathematics (NCSSM), a two-year public residential high school in Durham, NC.

Marshall Massengill, robotics mentor and alumnus of NCSSM, explains how Upverter has been helping him promote remote learning statewide. “Currently with Covid-19, most of our students are spread throughout the state rather than living on campus. Upverter’s collaborative nature is helping transform the team and keep on working, just as we would normally in the lab.” The Upverter Teachers Guide provides step by step instructions for teachers to launch the program.

For Michael Rosales, Engineering and Science teacher at Elk Grove Unified Florin High School, Altium’s education program is already changing the way he teaches Principles of Engineering. “This is perfect for my class already--it allows the kids to look at virtual circuits before they create physical ones, and you can have multiple people working on one circuit together,” Rosales reports.

Educators are currently using the program to teach robotics, engineering, digital electronics design, principles of engineering and STEM intro classes. The Upverter Education team is also supporting high school students working on proposals for NASA’s CubeSat Launch Initiative program, extending the use of Upverter for small satellite payloads.

To see how teachers are using Upverter Education in the classroom, please visit: https://youtu.be/cJu0Qopwk2M

For a comprehensive overview of the Upverter Education distance learning program, please register for this informational webinar , scheduled for February 27, 2021.

About Upverter

Upverter is a free EDA system delivered in a web-browser, which enables students and educators to design, share, and review schematics and printed circuit boards. It provides the ability to generate a bill of materials, Gerber files, and 3D rendering. Upverter is an Altium brand. To learn more about Upverter and Upverter Education, visit https://education.upverter.com/ .

ABOUT ALTIUM

Altium LLC, a global software company headquartered in San Diego, CA is accelerating the pace of innovation through electronics. For over 30 years, Altium has been delivering software that maximizes the productivity of PCB designers and electrical engineers. From individual inventors to multinational corporations, more PCB designers and engineers choose Altium software to design and realize electronics-based products.

Social Media:

https://www.facebook.com/AltiumOfficial

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye